Exact Sciences Corporation (EXAS)
US — Healthcare Sector
Automate Your Wheel Strategy on EXAS
With Tiblio's Option Bot, you can configure your own wheel strategy including EXAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXAS
- Rev/Share 16.2844
- Book/Share 13.2166
- PB 7.7561
- Debt/Equity 1.0135
- CurrentRatio 2.7226
- ROIC -0.1853
- MktCap 19468379369.0
- FreeCF/Share 1.3055
- PFCF 78.7929
- PE -19.6653
- Debt/Assets 0.4297
- DivYield 0
- ROE -0.4039
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXAS | Mizuho | Outperform | Neutral | -- | $105 | Jan. 20, 2026 |
| Downgrade | EXAS | Evercore ISI | Outperform | In-line | -- | $105 | Jan. 5, 2026 |
| Initiation | EXAS | Mizuho | -- | Outperform | -- | $60 | April 10, 2025 |
| Initiation | EXAS | RBC Capital Mkts | -- | Sector Perform | -- | $52 | March 13, 2025 |
| Initiation | EXAS | Barclays | -- | Overweight | -- | $70 | Jan. 23, 2025 |
| Initiation | EXAS | Wells Fargo | -- | Overweight | -- | $75 | Aug. 28, 2024 |
News
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
EXAS
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.
Read More
About Exact Sciences Corporation (EXAS)
- IPO Date 2001-02-01
- Website https://www.exactsciences.com
- Industry Medical - Diagnostics & Research
- CEO Kevin T. Conroy
- Employees 6900
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.